Las majestuosas ballenas, gigantes de los océanos que han fascinado a la humanidad durante siglos, enfrentan actualmente desafíos existenciales. Examinemos las amenazas que enfrentan y los esfuerzos internacionales para preservar estas magníficas criaturas marinas. El D …
El estado actual de la ecología de las ballenas y su lucha por la supervivencia Read More »
El cuerpo humano es una sinfonía química, una obra maestra de elementos que dan vida a cada célula, tejido y órgano. Os presentamos los elementos químicos y las cantidades que constituyen la asombrosa maquinaria biológica de nuestro organismo. Carbo …
Los elementos químicos que dan forma al cuerpo humano Read More »
Eli Lilly and Company announced updated clinical data from the international Phase 1/2 BRUIN trial of pirtobrutinib, a non-covalent Bruton’s tyrosine kinase inhibitor, in adult patients with a range of B-cell malignancies.
Global biotechnology leader CSL announced the three-year results from the pivotal HOPE-B study confirming continued long-term durability and safety of HEMGENIX® following a one-time infusion in people living with hemophilia B.
Legend Biotech Corporation, a global biotechnology company developing, manufacturing, and commercializing novel therapies to treat life-threatening diseases, announced patient-reported outcome data from the Phase 3 CARTITUDE-4 study from an oral presentation at the 2023 American Society of Hematology Annual Meeting.
Sensorion a pioneering clinical-stage biotechnology company which specializes in the development of novel therapies to restore, treat and prevent within the field of hearing loss disorders, announces the appointment of Bernd Schmidt, a senior leader with extensive experience in Chemistry, Manufacturing and Controls, as Chief Technical Officer, effective as of today.
Sensorion Appoints CMC Expert Bernd Schmidt as New Chief Technical Officer Read More »
Ascentage Pharma announced that it has released the results of lisaftoclax, one of the company’s key drug candidates, in patients with treatment-naïve or relapsed/refractory acute myeloid leukemia or other myeloid neoplasms, in a Poster Presentation at the 65th American Society of Hematology Annual Meeting, taking place in San Diego, CA, the United States.
Bristol Myers Squibb announced updated results from three key programs within its broad multiple myeloma research pipeline, highlighting its diverse targets and molecular approaches to address unique patient needs within the disease.
Johnson & Johnson announced new patient-reported outcomes from the Phase 3 CARTITUDE-4 study of CARVYKTI® demonstrated clinically meaningful improvements in health-related quality of life and meaningful reductions in disease-specific symptoms according to multiple PRO measures in the treatment of adult patients with relapsed and lenalidomide-refractory multiple myeloma who received one to three prior lines of
Bristol Myers Squibb and 2seventy bio, Inc. announced results from the preplanned final progression-free survival analysis of KarMMa-3, the pivotal Phase 3, open-label, global, randomized controlled study evaluating Abecma compared with standard combination regimens in adults with relapsed and refractory multiple myeloma after two to four prior lines of therapy.
